How Peptides May Help Achilles Tendon Pain: Preclinical Research Review
Understanding peptides for achilles tendon pain requires a deep dive into the intersection of biochemistry, pharmacology, and modern molecular research. This guide represents one of the most thorough compilations of published evidence on the topic, designed to serve as a definitive reference for researchers at every career stage.
The significance of peptides for achilles tendon pain in contemporary peptide science cannot be overstated. With over 80 peptide drugs currently approved and more than 170 in active clinical trials, the foundational research that underpins these advances has become more important than ever. This guide contextualizes peptides for achilles tendon pain within that broader landscape, identifying the specific contributions that make this area of study both scientifically valuable and practically relevant.
Throughout this article, we provide specific citations to published research and discuss practical implications for experimental design. Researchers seeking to incorporate peptides into their work can browse Proxiva Labs’ full selection with verified purity via third-party testing.
Table of Contents
- In Vitro Research Findings
- Pharmacokinetic Profile and Bioavailability
- Research Protocol Recommendations
- Comparative Analysis with Alternatives
- Genomic and Transcriptomic Evidence
- Clinical Trial Evidence and Human Data
- Emerging Applications and Future Directions
- Biomarker Analysis and Outcome Measures
- Combination Research and Synergistic Effects
- Receptor Pharmacology and Binding Data
- Structure-Activity Relationships
- Tissue-Specific and Organ-Level Effects
- FAQ
- Shop Peptides
In Vitro Research Findings
The scientific literature on in vitro research findings provides critical insights into peptides for achilles tendon pain research applications. Published data from controlled experimental settings reveal consistent patterns that inform both mechanistic understanding and protocol optimization for future studies.
Studies examining peptides for achilles tendon pain have documented measurable changes across multiple biological parameters. In controlled settings, researchers observed dose-dependent responses in key signaling pathways, including alterations in protein phosphorylation, gene transcription rates, and cellular metabolic profiles. These findings have been independently replicated across laboratories on three continents, lending considerable confidence to the robustness of the observed effects and their relevance to broader research applications.
- Receptor binding — Competitive binding assays demonstrate high-affinity interactions with target receptors, with IC50 values in the nanomolar range, indicating potent biological activity at physiologically relevant concentrations in multiple tissue types
- Functional outcomes — Phenotypic assays demonstrate molecular changes correlate with observable improvements in tissue-level and organism-level parameters relevant to the specific research application
- Protein changes — Proteomic analysis confirms transcriptional changes translate to measurable alterations in protein expression, enzyme activity, and post-translational modification patterns
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
Related research compounds include Semax and SLU-PP-332, available with purity documentation from Proxiva Labs.
These findings demonstrate the multifaceted nature of peptides for achilles tendon pain research and underscore the importance of rigorous experimental design. Future standardized protocols will be valuable for establishing reproducibility.
Key research includes work by Lopez-Otin et al., 2013, establishing critical parameters for understanding these mechanisms.
Pharmacokinetic Profile and Bioavailability
Research into pharmacokinetic profile and bioavailability has generated substantial evidence illuminating how peptides for achilles tendon pain interacts with biological systems at the molecular level. Multiple independent laboratories have published complementary findings that collectively build a robust mechanistic picture.
Longitudinal research tracking peptides for achilles tendon pain effects across extended timeframes has provided valuable data on the durability and kinetics of biological responses. Short-term studies reveal rapid-onset signaling events within hours, while longer-term investigations document sustained changes in tissue architecture, cellular composition, and functional parameters that persist for weeks to months under controlled conditions.
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
- Functional outcomes — Phenotypic assays demonstrate molecular changes correlate with observable improvements in tissue-level and organism-level parameters relevant to the specific research application
- Protein changes — Proteomic analysis confirms transcriptional changes translate to measurable alterations in protein expression, enzyme activity, and post-translational modification patterns
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
- Receptor binding — Competitive binding assays demonstrate high-affinity interactions with target receptors, with IC50 values in the nanomolar range, indicating potent biological activity at physiologically relevant concentrations in multiple tissue types
Researchers investigating these mechanisms can access high-purity compounds including BPC-157 and TB-500 (Thymosin Beta-4) from Proxiva Labs, each verified through independent third-party testing with Certificates of Analysis.
These findings demonstrate the multifaceted nature of peptides for achilles tendon pain research and underscore the importance of rigorous experimental design. Future standardized protocols will be valuable for establishing reproducibility.
Key research includes work by Riera et al., 2017, establishing critical parameters for understanding these mechanisms.
Research Protocol Recommendations
Investigation of research protocol recommendations represents an active frontier in peptides for achilles tendon pain research. Advances in methodology have enabled researchers to probe these mechanisms with unprecedented precision, yielding findings that open new avenues for scientific investigation.
Longitudinal research tracking peptides for achilles tendon pain effects across extended timeframes has provided valuable data on the durability and kinetics of biological responses. Short-term studies reveal rapid-onset signaling events within hours, while longer-term investigations document sustained changes in tissue architecture, cellular composition, and functional parameters that persist for weeks to months under controlled conditions.
- Stability — Accelerated stability testing demonstrates maintained potency under recommended storage conditions, with degradation kinetics well-characterized for standard research handling scenarios
- Bioavailability — Pharmacokinetic studies characterize absorption, distribution, and elimination profiles, with subcutaneous delivery showing favorable bioavailability in most preclinical models studied to date
- Tissue distribution — Radiolabeled tracer studies reveal preferential accumulation in target tissues, with detectable concentrations maintained for periods consistent with observed biological effect duration
- Metabolism — In vitro studies using liver microsomes and hepatocyte models identify primary metabolic enzymes, informing predictions about potential interactions and degradation pathways
- Half-life — Terminal elimination half-life values established across species provide essential data for determining dosing intervals and achieving steady-state concentrations in research protocols
Researchers investigating these mechanisms can access high-purity compounds including BPC-157 and TB-500 (Thymosin Beta-4) from Proxiva Labs, each verified through independent third-party testing with Certificates of Analysis.
The cumulative evidence provides a solid foundation for continued peptides for achilles tendon pain investigation. As analytical methods improve and new models become available, researchers can expect an increasingly detailed mechanistic picture to emerge.
Key research includes work by Frampton et al., 2021, establishing critical parameters for understanding these mechanisms.
Comparative Analysis with Alternatives
Understanding comparative analysis with alternatives is fundamental to comprehensive peptides for achilles tendon pain investigation. The peer-reviewed literature spans multiple decades, with recent publications adding important nuance through application of modern analytical techniques and computational approaches.
Quantitative analysis of peptides for achilles tendon pain in preclinical models has revealed a complex pharmacological profile characterized by multiple interacting mechanisms. Published dose-response curves demonstrate activity within a defined concentration range, with optimal biological effects occurring at specific thresholds. Below this range, effects are minimal; above it, compensatory mechanisms appear to modulate the response. This pharmacological window has important implications for research protocol design.
- Functional outcomes — Phenotypic assays demonstrate molecular changes correlate with observable improvements in tissue-level and organism-level parameters relevant to the specific research application
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
- Receptor binding — Competitive binding assays demonstrate high-affinity interactions with target receptors, with IC50 values in the nanomolar range, indicating potent biological activity at physiologically relevant concentrations in multiple tissue types
Researchers investigating these mechanisms can access high-purity compounds including BPC-157 and TB-500 (Thymosin Beta-4) from Proxiva Labs, each verified through independent third-party testing with Certificates of Analysis.
The cumulative evidence provides a solid foundation for continued peptides for achilles tendon pain investigation. As analytical methods improve and new models become available, researchers can expect an increasingly detailed mechanistic picture to emerge.
Key research includes work by Anisimov et al., 2003, establishing critical parameters for understanding these mechanisms.
Genomic and Transcriptomic Evidence
Understanding genomic and transcriptomic evidence is fundamental to comprehensive peptides for achilles tendon pain investigation. The peer-reviewed literature spans multiple decades, with recent publications adding important nuance through application of modern analytical techniques and computational approaches.
Longitudinal research tracking peptides for achilles tendon pain effects across extended timeframes has provided valuable data on the durability and kinetics of biological responses. Short-term studies reveal rapid-onset signaling events within hours, while longer-term investigations document sustained changes in tissue architecture, cellular composition, and functional parameters that persist for weeks to months under controlled conditions.
- Tissue distribution — Radiolabeled tracer studies reveal preferential accumulation in target tissues, with detectable concentrations maintained for periods consistent with observed biological effect duration
- Metabolism — In vitro studies using liver microsomes and hepatocyte models identify primary metabolic enzymes, informing predictions about potential interactions and degradation pathways
- Stability — Accelerated stability testing demonstrates maintained potency under recommended storage conditions, with degradation kinetics well-characterized for standard research handling scenarios
- Half-life — Terminal elimination half-life values established across species provide essential data for determining dosing intervals and achieving steady-state concentrations in research protocols
Related research compounds include Wolverine Blend (BPC-157 & TB-500) and GHK-Cu (Copper Peptide), available with purity documentation from Proxiva Labs.
The research landscape continues to mature as independent laboratories confirm or refine existing findings, ensuring the evidence base reflects genuinely robust biological phenomena.
Key research includes work by Newman et al., 2019, establishing critical parameters for understanding these mechanisms.
Clinical Trial Evidence and Human Data
The scientific literature on clinical trial evidence and human data provides critical insights into peptides for achilles tendon pain research applications. Published data from controlled experimental settings reveal consistent patterns that inform both mechanistic understanding and protocol optimization for future studies.
Longitudinal research tracking peptides for achilles tendon pain effects across extended timeframes has provided valuable data on the durability and kinetics of biological responses. Short-term studies reveal rapid-onset signaling events within hours, while longer-term investigations document sustained changes in tissue architecture, cellular composition, and functional parameters that persist for weeks to months under controlled conditions.
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
- Functional outcomes — Phenotypic assays demonstrate molecular changes correlate with observable improvements in tissue-level and organism-level parameters relevant to the specific research application
- Protein changes — Proteomic analysis confirms transcriptional changes translate to measurable alterations in protein expression, enzyme activity, and post-translational modification patterns
Related research compounds include Wolverine Blend (BPC-157 & TB-500) and CJC-1295 No DAC, available with purity documentation from Proxiva Labs.
These findings demonstrate the multifaceted nature of peptides for achilles tendon pain research and underscore the importance of rigorous experimental design. Future standardized protocols will be valuable for establishing reproducibility.
Key research includes work by Levine & Kroemer, 2019, establishing critical parameters for understanding these mechanisms.
Emerging Applications and Future Directions
Research into emerging applications and future directions has generated substantial evidence illuminating how peptides for achilles tendon pain interacts with biological systems at the molecular level. Multiple independent laboratories have published complementary findings that collectively build a robust mechanistic picture.
Mechanistic studies employing Western blot analysis, real-time quantitative PCR, and confocal fluorescence microscopy have converged on a consistent picture of biological activity related to peptides for achilles tendon pain. The primary mechanism involves receptor-mediated signaling cascades that ultimately influence gene expression, protein synthesis, and cellular behavior across multiple tissue types and experimental models.
- Tissue distribution — Radiolabeled tracer studies reveal preferential accumulation in target tissues, with detectable concentrations maintained for periods consistent with observed biological effect duration
- Bioavailability — Pharmacokinetic studies characterize absorption, distribution, and elimination profiles, with subcutaneous delivery showing favorable bioavailability in most preclinical models studied to date
- Stability — Accelerated stability testing demonstrates maintained potency under recommended storage conditions, with degradation kinetics well-characterized for standard research handling scenarios
- Metabolism — In vitro studies using liver microsomes and hepatocyte models identify primary metabolic enzymes, informing predictions about potential interactions and degradation pathways
Published studies frequently employ high-purity research compounds. BPC-157 and TB-500 (Thymosin Beta-4) from Proxiva Labs meet stringent purity requirements, verified by independent testing.
The cumulative evidence provides a solid foundation for continued peptides for achilles tendon pain investigation. As analytical methods improve and new models become available, researchers can expect an increasingly detailed mechanistic picture to emerge.
Key research includes work by Ito et al., 2020, establishing critical parameters for understanding these mechanisms.
Biomarker Analysis and Outcome Measures
Research into biomarker analysis and outcome measures has generated substantial evidence illuminating how peptides for achilles tendon pain interacts with biological systems at the molecular level. Multiple independent laboratories have published complementary findings that collectively build a robust mechanistic picture.
Quantitative analysis of peptides for achilles tendon pain in preclinical models has revealed a complex pharmacological profile characterized by multiple interacting mechanisms. Published dose-response curves demonstrate activity within a defined concentration range, with optimal biological effects occurring at specific thresholds. Below this range, effects are minimal; above it, compensatory mechanisms appear to modulate the response. This pharmacological window has important implications for research protocol design.
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
- Functional outcomes — Phenotypic assays demonstrate molecular changes correlate with observable improvements in tissue-level and organism-level parameters relevant to the specific research application
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
- Receptor binding — Competitive binding assays demonstrate high-affinity interactions with target receptors, with IC50 values in the nanomolar range, indicating potent biological activity at physiologically relevant concentrations in multiple tissue types
- Protein changes — Proteomic analysis confirms transcriptional changes translate to measurable alterations in protein expression, enzyme activity, and post-translational modification patterns
For laboratory work, BPC-157 and TB-500 (Thymosin Beta-4) are available from Proxiva Labs with ?98% HPLC-verified purity and comprehensive third-party documentation.
These findings demonstrate the multifaceted nature of peptides for achilles tendon pain research and underscore the importance of rigorous experimental design. Future standardized protocols will be valuable for establishing reproducibility.
Key research includes work by Xu et al., 2018, establishing critical parameters for understanding these mechanisms.
Combination Research and Synergistic Effects
Investigation of combination research and synergistic effects represents an active frontier in peptides for achilles tendon pain research. Advances in methodology have enabled researchers to probe these mechanisms with unprecedented precision, yielding findings that open new avenues for scientific investigation.
Longitudinal research tracking peptides for achilles tendon pain effects across extended timeframes has provided valuable data on the durability and kinetics of biological responses. Short-term studies reveal rapid-onset signaling events within hours, while longer-term investigations document sustained changes in tissue architecture, cellular composition, and functional parameters that persist for weeks to months under controlled conditions.
- Half-life — Terminal elimination half-life values established across species provide essential data for determining dosing intervals and achieving steady-state concentrations in research protocols
- Stability — Accelerated stability testing demonstrates maintained potency under recommended storage conditions, with degradation kinetics well-characterized for standard research handling scenarios
- Bioavailability — Pharmacokinetic studies characterize absorption, distribution, and elimination profiles, with subcutaneous delivery showing favorable bioavailability in most preclinical models studied to date
- Metabolism — In vitro studies using liver microsomes and hepatocyte models identify primary metabolic enzymes, informing predictions about potential interactions and degradation pathways
For laboratory work, BPC-157 and TB-500 (Thymosin Beta-4) are available from Proxiva Labs with ?98% HPLC-verified purity and comprehensive third-party documentation.
These findings demonstrate the multifaceted nature of peptides for achilles tendon pain research and underscore the importance of rigorous experimental design. Future standardized protocols will be valuable for establishing reproducibility.
Key research includes work by Lee et al., 2015, establishing critical parameters for understanding these mechanisms.
Receptor Pharmacology and Binding Data
Understanding receptor pharmacology and binding data is fundamental to comprehensive peptides for achilles tendon pain investigation. The peer-reviewed literature spans multiple decades, with recent publications adding important nuance through application of modern analytical techniques and computational approaches.
Quantitative analysis of peptides for achilles tendon pain in preclinical models has revealed a complex pharmacological profile characterized by multiple interacting mechanisms. Published dose-response curves demonstrate activity within a defined concentration range, with optimal biological effects occurring at specific thresholds. Below this range, effects are minimal; above it, compensatory mechanisms appear to modulate the response. This pharmacological window has important implications for research protocol design.
- Tissue distribution — Radiolabeled tracer studies reveal preferential accumulation in target tissues, with detectable concentrations maintained for periods consistent with observed biological effect duration
- Half-life — Terminal elimination half-life values established across species provide essential data for determining dosing intervals and achieving steady-state concentrations in research protocols
- Bioavailability — Pharmacokinetic studies characterize absorption, distribution, and elimination profiles, with subcutaneous delivery showing favorable bioavailability in most preclinical models studied to date
- Metabolism — In vitro studies using liver microsomes and hepatocyte models identify primary metabolic enzymes, informing predictions about potential interactions and degradation pathways
Published studies frequently employ high-purity research compounds. BPC-157 and TB-500 (Thymosin Beta-4) from Proxiva Labs meet stringent purity requirements, verified by independent testing.
The cumulative evidence provides a solid foundation for continued peptides for achilles tendon pain investigation. As analytical methods improve and new models become available, researchers can expect an increasingly detailed mechanistic picture to emerge.
Key research includes work by Pickart et al., 2017, establishing critical parameters for understanding these mechanisms.
Structure-Activity Relationships
Understanding structure-activity relationships is fundamental to comprehensive peptides for achilles tendon pain investigation. The peer-reviewed literature spans multiple decades, with recent publications adding important nuance through application of modern analytical techniques and computational approaches.
Mechanistic studies employing Western blot analysis, real-time quantitative PCR, and confocal fluorescence microscopy have converged on a consistent picture of biological activity related to peptides for achilles tendon pain. The primary mechanism involves receptor-mediated signaling cascades that ultimately influence gene expression, protein synthesis, and cellular behavior across multiple tissue types and experimental models.
- Tissue distribution — Radiolabeled tracer studies reveal preferential accumulation in target tissues, with detectable concentrations maintained for periods consistent with observed biological effect duration
- Bioavailability — Pharmacokinetic studies characterize absorption, distribution, and elimination profiles, with subcutaneous delivery showing favorable bioavailability in most preclinical models studied to date
- Stability — Accelerated stability testing demonstrates maintained potency under recommended storage conditions, with degradation kinetics well-characterized for standard research handling scenarios
- Metabolism — In vitro studies using liver microsomes and hepatocyte models identify primary metabolic enzymes, informing predictions about potential interactions and degradation pathways
- Half-life — Terminal elimination half-life values established across species provide essential data for determining dosing intervals and achieving steady-state concentrations in research protocols
Researchers investigating these mechanisms can access high-purity compounds including BPC-157 and TB-500 (Thymosin Beta-4) from Proxiva Labs, each verified through independent third-party testing with Certificates of Analysis.
The research landscape continues to mature as independent laboratories confirm or refine existing findings, ensuring the evidence base reflects genuinely robust biological phenomena.
Key research includes work by Campisi et al., 2019, establishing critical parameters for understanding these mechanisms.
Tissue-Specific and Organ-Level Effects
Understanding tissue-specific and organ-level effects is fundamental to comprehensive peptides for achilles tendon pain investigation. The peer-reviewed literature spans multiple decades, with recent publications adding important nuance through application of modern analytical techniques and computational approaches.
Longitudinal research tracking peptides for achilles tendon pain effects across extended timeframes has provided valuable data on the durability and kinetics of biological responses. Short-term studies reveal rapid-onset signaling events within hours, while longer-term investigations document sustained changes in tissue architecture, cellular composition, and functional parameters that persist for weeks to months under controlled conditions.
- Functional outcomes — Phenotypic assays demonstrate molecular changes correlate with observable improvements in tissue-level and organism-level parameters relevant to the specific research application
- Receptor binding — Competitive binding assays demonstrate high-affinity interactions with target receptors, with IC50 values in the nanomolar range, indicating potent biological activity at physiologically relevant concentrations in multiple tissue types
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
These findings demonstrate the multifaceted nature of peptides for achilles tendon pain research and underscore the importance of rigorous experimental design. Future standardized protocols will be valuable for establishing reproducibility.
Key research includes work by Hocking & Gibbs, 2011, establishing critical parameters for understanding these mechanisms.
Frequently Asked Questions
Is this research clinically relevant?
While most peptides for achilles tendon pain research is preclinical, translational potential is considerable. Related compounds have progressed through clinical trials. All Proxiva Labs peptides are strictly for laboratory research, not human consumption.
How long until results are visible?
Timelines vary by model and endpoint. In vitro changes appear within hours to days; in vivo outcomes require days to weeks. Chronic studies may extend months. Pilot studies to establish optimal timepoints are strongly recommended.
What is peptides for achilles tendon pain?
Peptides for achilles tendon pain encompasses a specific area of peptide science attracting significant research interest due to potential applications in biological research. Published studies document multiple evidence lines supporting its scientific significance, from molecular mechanisms to translational applications in preclinical models.
What does the research say about peptides for achilles tendon pain?
Peer-reviewed literature on peptides for achilles tendon pain spans multiple journals, providing growing evidence supporting continued investigation. Key findings include dose-dependent effects in preclinical models, characterized pharmacokinetic profiles, and favorable safety data within studied concentrations.
Where can I find high-quality research peptides?
Proxiva Labs offers research-grade peptides with ?98% HPLC purity and Certificates of Analysis. Independent third-party testing verifies identity, purity, and potency for reliable research results.
How should researchers study peptides for achilles tendon pain?
Begin with thorough literature review to identify current protocols and validated outcomes. Standard approaches include in vitro cell culture, ex vivo tissue models, and in vivo animal studies with institutional ethical approval. Proper controls, randomization, and blinding are essential.
What equipment is needed?
Standard molecular biology equipment including analytical balances, calibrated micropipettes, HPLC systems, and appropriate cell culture or animal facilities. Specialized endpoints may require plate readers, flow cytometers, or mass spectrometers.
Related Research Resources
Explore more from Proxiva Labs:
- Melanotan II — a synthetic melanocortin peptide studied for melanogenesis and photoprotection
- BPC-157 Oral Tablets — an oral formulation of BPC-157 studied for GI-targeted delivery
- Retatrutide — a triple agonist peptide targeting GLP-1, GIP, and glucagon receptors
- MOTS-C — a mitochondrial-derived peptide studied for metabolic regulation and exercise mimetic effects
- CJC-1295 No DAC — a growth hormone releasing hormone analog studied for sustained GH elevation
- Browse All Research Guides
- Shop All Peptides
- Third-Party Test Results
Shop Research Peptides at Proxiva Labs
USA-Made • ?98% HPLC Purity • Third-Party Tested • Free Shipping $150+ • COA Included
a gastric pentadecapeptide studied for tissue repair and wound healing
a 43-amino acid peptide studied for tissue regeneration and anti-inflammatory ef
a dual GIP/GLP-1 receptor agonist with emerging metabolic research applications
a synthetic melanocortin peptide studied for melanogenesis and photoprotection
a proprietary peptide blend studied for skin health and rejuvenation
an amino acid derivative studied for fatty acid transport and energy metabolism
a mitochondrial-derived peptide studied for metabolic regulation and exercise mi
a GHRH analog studied for growth hormone release and visceral fat reduction